Authors : Shanowaj Kabir; Dr. Nilanjan Pahari; Amit Maity; Rudraneel Sarkar

Volume/Issue : Volume 11 - 2026, Issue 2 - February

Google Scholar : https://tinyurl.com/2s83vs6v

Scribd : https://tinyurl.com/29b38856

DOI : https://doi.org/10.38124/ijisrt/26feb693

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : This study examined the neuroprotective effects of ethanolic leaf extract from Causonis trifolia (L.) on Alzheimer's disease in Wistar rats produced by aluminum chloride (AlCl3). Bioactive substances like 9-octadecanoic acid were found by phytochemical and GC-MS studies, and molecular docking supported their interaction with important targets for Alzheimer's disease. In vivo tests revealed that, in comparison to untreated disease controls, treatment with the extract at doses of 150 and 300 mg/kg, along with donepezil, significantly increased locomotor activity, decreased anxiety, and improved memory retention in behavioral tests (IR Actimeter, Elevated Plus Maze, and Novel Object Recognition). Furthermore, the extract reduced neurodegenerative damage in striatal tissue and restored antioxidant enzyme activity (SOD and CAT). All things considered, the results show that Causonis trifolia has encouraging anti-Alzheimer's properties, most likely due to its antioxidant processes.

References :

1.  Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid ß deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: A prospective cohort study. Lancet Neurol. 2013;12(4):357- 367.
2. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease in the presenilin 1 E280A kindred: A case-control study. Lancet Neurol. 2012;11(2):1048- 1056.
3. Jack CR, Lowe VJ, Weigand SD, et al. Serial PiB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: Implications for sequence of pathological events in Alzheimer’s disease. Brain. 2009; 132:1355-1365.
4. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795-804.
5. Gordon BA, Blazey TM, Su Y, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: A longitudinal study. Lancet Neurol. 2018;17(3):241-250.
6. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960-969.
7. Quiroz YT, Zetterberg H, Reiman EM, et al. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer’s disease kindred: A cross-sectional and longitudinal cohort study. Lancet Neuro. 2020;19(6):513-521.
8. Barthelemy N, Joseph-Mathurin N, Gordon BA, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat Med. 2020; 26:398-407.
9. Byard RW, Langlois NEI. Wandering dementia: A syndrome with forensic implications. J Forensic Sci. 2019;64(2):443-445.
10. Tom SE, Hubbard RA, Crane PK, et al. Characterization of dementia and Alzheimer’s disease in an older population: Updated incidence and life expectancy with and without dementia. Am J Public Health. 2015;105(2):408-413.
11. Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST. Alzheimer disease and mortality: A 15-year epidemiological study. Arch Neurol. 2005;62(5):779-784.
12. Waring SC, Doody RS, Pavlik VN, Massman PJ, Chan W. Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord. 2005;19(4):178183.
13. Brookmeyer R, Corrada MM, Curriero FC, Kawas C. Survival following a diagnosis of Alzheimer disease. Arch Neurol. 2002;59(11):1764-1767.
14. Larson EB, Shadlen MF, Wang L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med. 2004;140(7):501-509.
15. Helzner EP, Scarmeas N, Cosentino S, Tang MX, Schupf N, Stern Y. Survival in Alzheimer disease: A multiethnic, populationbased study of incident cases. Neurology. 2008;71(19):1489- 1495.
16. Xie J, Brayne C, Matthews FE. Survival times in people with dementia: Analysis from a population-based cohort study with 14-year follow-up. BMJ. 2008;336(7638):258- 262.
17. Brodaty H, Seeher K, Gibson L. Dementia time to death: A systematic literature review on survival time and years of life lost in people with dementia. Int Psychogeriatr. 2012;24(7):1034-1045.
18. Todd S, Barr S, Roberts M, Passmore AP. Survival in dementia and predictors of mortality: A review. Int J Geriatr Psychiatry. 2013;28(11):1109-1124.
19. World Health Organization. Dementia: Key facts. Accessed October 10, 2023. Available at: https://www.who.int/news-room/factsheets/detail/dementia.
20. Smith AD, Smith SM, de Jager, CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial.Plos One. 2010;5(9): e12244.
21. Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134(2):171-186.
22. Brenowitz WD, Hubbard RA, Keene CD, et al. Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. Alzheimers Dement. 2017;13(6):654-662.
23. National Institute on Aging. What are frontotemporal disorders? Accessed December 16, 2023. Available at: https://www.nia.nih. gov/health/what-are- frontotemporal-disorders.
24. Hogan DB, Jette N, Fiest KM, et al. The prevalence and incidence of frontotemporal dementia: A systematic review. Can J Neurol Sci. 2016;43(suppl): S96-109.
25. Amador-Ortiz C, Ahmed Z, Zehr C, Dickson DW. Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration. Acta Neuropathol. 2007;113(3):245252.
26. Kane JPM, Surendranathan A, Bentley A, Thomas AJ, et al. Clinical prevalence of Lewy body dementia. Alzheimers Res Ther. 2018 Feb 15;10(1):19.
27. De Reuck J, Maurage CA, Deramecourt V, et al. Aging and cerebrovascular lesions in pure and in mixed neurodegenerative and vascular dementia brains: A neuropathological study. Folia Neuropathol. 2018;56(2):81-87.
28. James BD, Bennett DA, Boyle PA, Leurgans S, Schneider JA. Dementia from Alzheimer disease and mixed pathologies in the oldest old. JAMA. 2012;307(17):1798-1800.
29. Stojkovska I, Krainc D, Mazzulli JR. Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease. Cell Tissue Res. 2018;373(1):51-60.
30. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005;20(10):1255.
31. Kawas CH, Kim RC, Sonnen JA, Bullain SS, Trieu T, Corrada MM. Multiple pathologies are common and related to dementia in the oldest-old: The 90+ Study. Neurology. 2015;85(6):535- 542.
32. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: How to move forward? Neurology. 2009; 72:368-374.
33. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in communitydwelling older persons. Neurology. 2007; 69:2197- 2204.
34. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66(2):200-208.
35. Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. J Neurol Sci. 2007;257(1-2):80-87.
36. Jellinger KA. The enigma of mixed dementia. Alzheimers Dement. 2007;3(1):40-53.
37. Boyle PA, Lei Y, Wilson RS, Leurgans SE, Schneider JA, Bennett DA. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018;83(1):74-83.
38. Boyle PA, Yu L, Leurgans SE, et al. Attributable risk of Alzheimer’s dementia attributed to age-related neuropathologies. Ann Neurol. 2019;85(1):114-124.
39. Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol. 2010; 119:421- 433.
40. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging- Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280-292.
41. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on AgingAlzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270-279.
42. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging- Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263-269.
43. Jack CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):257-262.
44. Vermunt L, Sikkes SAM, van den Hout A, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype.Alzheimers Dement. 2019; 15:888-898.
45. Sperling RA, Donohue MC, Raman R, et al. Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol. 2020;77(6):735-745.
46. Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673684.
47. Hunt A, Schonknecht P, Henze M, Seidl U, Haberkorn U, Schroder J. Reduced cerebral glucose metabolism in patients at risk for Alzheimer’s disease. Psych Res: Neuroimaging. 2007; 155:147-154.
48. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two communitybased studies. Neurology. 2006; 66:1837- 1844.
49. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003; 62:1087-1095.
50. Grontvedt GR, Schroder TN, Sando SB, White L, Brathen G, Doeller CF. Alzheimer’s disease. Curr Bio. 2018;28:PR645-PR649.
51. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment. Neurology. 2018;90(3):126-135.
52. Ward A, Tardiff S, Dye C, Arrighi HM. Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia: A systematic review of the literature. Dement Geriatr Cogn Disord Extra. 2013;3(1):320-332.
53. Canevelli M, Grande G, Lacorte E, et al. Spontaneous reversion of mild cognitive impairment to normal cognition: A systematic review of literature and meta-analysis. J Am Med Dir Assoc. 2016;17(10):943-948.
54. Social Security Administration. Minimizing the risk of scams for people living with dementia. Accessed October 11, 2023. Available at: https://blog.ssa.gov/minimizing-the- riskof-scams-forpeople-living-with-dementia/#:∼:text=People%20living%20with% 20dementia%20are, struggle%20to%20make%20financial% 20decisions
55. Memory and Aging Center, UCSF Weill Institute for Neurosciences. Executive functions. Accessed  October  11,          2023.    Available               at: https://memory.ucsf.edu/symptoms/executivefunctions.
56. Heerema E. How executive functioning Is affected by dementia. Verywell Health. Accessed                October  30,          2023.    Available               at: https://www.verywellhealth.com/executivefunctioningalzheimers-98596.
57. Beshir SA, Aadithsoorya AM, Parveen A, Goh SSL, Hussain N, Menon VB. Aducanumab therapy to treat Alzheimer’s disease: A narrative review. Int J Alzheimers Dis. 2022; 2022:9343514.
58. Van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023; 388:9-21.
59. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362- 377.
60. Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: Appropriate use recommendations. J Prev Alz Dis. 2021;4(8):398-410.
61. Cummings J, Rabinovici GD, Atri A. et al. Aducanumab: Appropriate Use Recommendations Update. J Prev Alzheimers Dis. 2022; 9:221- 230.
62. Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer’s disease drug development timeline: 2023. Alzheimers Dement: TRCI 2023. doi:10.1002/trc2.12385.
63. Lim MM, Gerstner JR, Holtzman DM. The sleep-wake cycle and Alzheimer’s disease: What do we know? Neurodegener Dis Manag. 2014;4(5):351-362.
64. Lloret M-A, Cervera-Ferri A, Nepomuceno M, Monllor P, Esteve D, Lloret A. Is sleep disruption a cause or consequence of Alzheimer’s disease? Reviewing its possible role as a biomarker. Int J Mol Sci. 2020; 21:1168.
65. Rose KM, Fagin CM, Lorenz R. Sleep Disturbances in Dementia: What They Are and What To Do. J Gerontol Nurs. 2010;36(5):9-14.
66. Van der Mussele S, Le Bastard N, et al. Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer’s dementia. Aging Ment Health. 2015;19(3):247- 257.
67. Watt JA, Goodarzi Z, Veroniki AA, et al. Comparative efficacy of interventions for aggressive and agitated behaviors in dementia. Ann Internal Med. 2019;171(9):633-642.
68. Ralph SJ, Espinet AJ. Increased all-cause mortality by antipsychotic drugs: Updated review and meta-analysis in dementia and general mental health care. J Alzheimers Dis Rep. 2018; 2:1-26.
69. Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015; 72:438445.
70. Hebert LE, Bienias JL, Aggarwal NT, et al. Change in risk of Alzheimer disease over time.Neurology. 2010; 75:786-791.
71. National Institute on Aging. Accessed December 15, 2023. Available at: https://www.nia.nih.gov/health/what-causes-alzheimersdisease.
72. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology. 1993; 43:14671472.
73. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. JAMA. 1997; 278:1349- 1356.
74. Green RC, Cupples LA, Go R, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA. 2002;287(3):329-336.
75. Fratiglioni L, Ahlbom A, Viitanen M, Winblad B. Risk factors for lateonset Alzheimer’s disease: A population-based, case-control study. Ann Neurol. 1993;33(3):258-266.
76. Mayeux R, Sano M, Chen J, Tatemichi T, Stern Y. Risk of dementia in first-degree relatives of patients with Alzheimer’s disease and related disorders. Arch Neurol. 1991;48(3):269-273.
77. Lautenschlager NT, Cupples LA, Rao VS, et al. Risk of dementia among relatives of Alzheimer’s disease patients in the MIRAGE Study: What is in store for the oldest old? Neurology. 1996;46(3):641-650.
78. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (20102050) estimated using the 2010 Census. Neurology. 2013;80(19):1778-1783.
79. Nelson PT, Head E, Schmitt FA, et al. Alzheimer’s disease is not “brain aging”: Neuropathological, genetic, and epidemiological human studies. Acta Neuropathol. 2011; 121:571-587.
80. Bellenguez C, Küçükali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet. 2022; 54:412-436.
81. Loy CT, Schofield PR, Turner AM, Kwok JBJ. Genetics of dementia. Lancet. 2014; 383:828-840.
82. Qian J, Wolters FJ, Beiser A, et al. APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. PLoS Med. 2017;14(3): e1002254.
83. Spinney L. Alzheimer’s disease: The forgetting gene. Nature. 2014;510(7503):26-28.
84. Ward A, Crean S, Mercaldi CJ, et al. Prevalence of apolipoprotein e4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer’s disease: A systematic review and meta-analysis. Neuroepidemiology. 2012; 38:1-17.
85. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. N Engl J Med. 1998; 338:506-511.
86. Evans DA, Bennett DA, Wilson RS, et al. Incidence of Alzheimer disease in a biracial urban community: Relation to apolipoprotein E allele status. Arch Neurol. 2003;60(2):185189.
87. Tang M, Stern Y, Marder K, et al. The APOE-e4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998; 279:751-755.
88. Weuve J, Barnes LL, Mendes de Leon CF, et al. Cognitive aging in black and white Americans: Cognition, cognitive decline, and incidence of Alzheimer disease dementia. Epidemiology. 2018;29(1):151-159.
89. Hendrie HC, Murrell J, Baiyewu O, et al. APOE ε4 and the risk for Alzheimer disease and cognitive decline in African Americans and Yoruba. Int Psychogeriatr. 2014;26(6):977- 985.
90. Reitz C, Jun G, Naj A, et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E epsilon 4, and the risk of late-onset Alzheimer disease in African Americans.JAMA. 2013;309(14):1483-1492.
91. Gottesman RF, Albert MS, Alonso A, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol. 2017;74(10):1246-1254.
92. Bakulski KM, Vadari HS, Faul JD, et al. Cumulative genetic risk and APOE «4 are independently associated with dementia status in a multiethnic, population-based cohort. Neurol Genet. 2021;7: e576.
93. Rajan KB, Barnes LL, Wilson RS, et al. Racial differences in the association between apolipoprotein E risk alleles and overall and total cardiovascular mortality over 18 years. JAGS. 2017; 65:2425- 2430.
94. Kataoka S, Robbins DC, Cowan LD, et al. Apolipoprotein E polymorphism in American Indians and its relation to plasma lipoproteins and diabetes. The Strong Heart Study. Arterioscler Thromb Vasc Biol. 1996; 16:918-925.
95. Le Guen Y, Raulin AC, Logue MW, et al. Association of African ancestry-specific APOE missense variant R145C with risk of Alzheimer disease. JAMA. 2023;329(7):551- 560.
96. Granot-Hershkovitz E, Tarraf W, Kurniansyah N, et al. APOE alleles’ associationn with cognitive function differs across Hispanic/Latino groups and genetic ancestry in the study of Latinosinvestigation of neurocognitive aging (HCHS/SOL). Alzheimer’s Dement. 2021; 17:466-474.
97. Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down’s syndrome. Lancet Neurol. 2010;9(6):623-633.
98. National Down Syndrome Society. Alzheimer’s Disease and Down Syndrome. Accessed December 15, 2023. Available at: https:// www.ndss.org/resources/alzheimers/.
99. Fortea J, Vilaplana E, Carmona-Iragui M, et al. Clinical and biomarker changes of Alzheimer’s disease in adults with Down syndrome: A cross-sectional study. Lancet. 2020;395(10242):1988- 1997.
100. Fortea J, Zaman SH, Hartley S, Rafii MS, Head E, Carmona-Iragui M. Alzheimer’s disease associated with Down syndrome: A genetic form of dementia. Lancet Neurol. 2021;20(11):930-942.
101. Hithersay R, Startin CM, Hamburg S, et al. Association of dementia with mortality among adults with Down syndrome older than 35 years. JAMA Neurol. 2019;76(2):152-160.
102. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23(4):213-227.
103. Goldman JS, Hahn SE, Bird T. Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med. 2011; 13:597-605.
104. Lopera F, Marino C, Chandrahas AS, et al. Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man. Nat Med. 2023 May;29(5):12431252.
105. Arboleda-Velasquez JF, Lopera F, O’Hare M, et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25(11):1680-1683.